Hyperthyroidism – Global Clinical Trials Review, H2, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData’s clinical trial report provides an overview of the hyperthyroidism clinical trials scenario. This report provides top-line data relating to the clinical trials on Hyperthyroidism. The report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. The report also provides prominent drugs for in-progress trials (based on several ongoing trials). GlobalData clinical trial Reports are generated using GlobalData’s proprietary database – Pharma – clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news, etc across the globe. Clinical trials database undergoes periodic updates by dynamic process.
The hyperthyroidism clinical trial report consists of 121 trials. Trials conducted by companies in Phase IV, Phase III, Phase II, and Phase I stand at 2, 4, 6, and 31 respectively. Similarly, the trials with different status compile of completed – 84, ongoing – 16, planned – 11, terminated – 5, and withdrawn – 5. Out of 84 completed trials 47 trials have achieved endpoint.
What are the market dynamics of the global hyperthyroidism therapeutics clinical trials sector?
The number of hyperthyroidism clinical trials conducted globally has decreased by over 57% for the period 2016-2020. The average number of patients enrolled was highest in the year 2019. As of December 2021, out of 84 completed trials, 59 trials have results and 80% of trials reached endpoints. Out of the total clinical trials conducted, over 61% of trials have been sponsored by institutions and 31% by companies.
What are the top regions and countries in the global hyperthyroidism therapeutics clinical trials sector? In total there were 121 clinical trials conducted on hyperthyroidism, as of December 2021, of these 44 clinical trials were in Asia-Pacific. During the same period, China has the highest average patient enrollment in hyperthyroidism clinical trials.
Asia-Pacific: In the Asia-Pacific region, China has the highest number of hyperthyroidism clinical trials followed by Japan, Indonesia, Thailand, and Malaysia.
Europe: Among the European countries, Italy has the highest number of hyperthyroidism clinical trials followed by the Netherlands, the UK, Denmark, and Germany.
Middle East and Africa: Iran has the highest number of hyperthyroidism clinical trials followed by Cameroon and South Africa.
North America: The US has the highest number of hyperthyroidism clinical trials followed by Canada.
South and Central America: Brazil has the highest number of hyperthyroidism clinical trials, as of December 2021.
G7 countries: Among the G7 (The US, the UK, Germany, France, Italy, Canada, and Japan) countries, the UK has the highest proportion of hyperthyroidism to hormonal disorders clinical trials as of December 2021. In total there were 33 clinical trials conducted on Hyperthyroidism, in G7 countries, of these 8 clinical trials were in Italy. During the same period, there were two clinical trials in progress and 19 trials are completed. The trials that are terminated/suspended or withdrawn accounted for 3.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Indonesia has the highest proportion of hyperthyroidism to hormonal disorders clinical trials as of December 2021. In total there were 33 clinical trials conducted on Hyperthyroidism, in E7 Countries, of these 28 clinical trials were in China. During the same period, there were five clinical trials in progress and 18 trials were completed. The trials that were terminated/suspended or withdrawn accounted for 4.
Global hyperthyroidism therapeutics clinical trials sector, by regions
For more regional insights, download a free report sample
Which are the key companies in the global hyperthyroidism therapeutics clinical trials sector?
As of December 2021, Morningside Healthcare Ltd sponsored the highest number of hyperthyroidism clinical trials followed by Macleods Pharmaceuticals Ltd and Uni-Pharma SA. Other major companies in the sector are Roivant Sciences Ltd, Novartis AG, Health Sciences Acquisitions Corp 2, Beijing Yanjing Pharmaceutical Co Ltd, Beijing Borui Kangjian Pharmaceutical Technology Co Ltd, Beijing Baiao Pharmaceuticals Co Ltd, and AbbVie Inc.
Global hyperthyroidism therapeutics clinical trials sector, by key companies
To know more about key companies, download a free report sample
Market report scope
Key countries | The US, the UK, the Netherlands, Denmark, Malaysia, Spain, Italy, Iran, and China |
Key companies | Morningside Healthcare Ltd, Macleods Pharmaceuticals Ltd, Uni-Pharma SA, Roivant Sciences Ltd, Novartis AG, Health Sciences Acquisitions Corp 2, Beijing Yanjing Pharmaceutical Co Ltd, Beijing Borui Kangjian Pharmaceutical Technology Co Ltd, Beijing Baiao Pharmaceuticals Co Ltd, and AbbVie Inc |
Scope
- The report provides a snapshot of the global clinical trials landscape.
- The Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status.
- The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company.
- The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with the reason for unaccomplishment.
- The Report provides enrollment trends for the past five years.
- The Report provides the latest news for the past three months.
Reasons to Buy
- Assists in formulating key business strategies with regard to investment.
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost.
- Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities.
- Supports understanding of trials count and enrollment trends by country in the global therapeutics market.
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials.
- Facilitates clinical trial assessment of the indication on a global, regional, and country-level.
Macleods Pharmaceuticals Ltd
Uni-Pharma SA
Health Sciences Acquisitions Corp 2
Novartis AG
Roivant Sciences Ltd
AbbVie Inc
Beijing Baiao Pharmaceuticals Co Ltd
Beijing Borui Kangjian Pharmaceutical Technology Co Ltd
Beijing Yanjing Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key countries in the global hyperthyroidism therapeutics clinical trials sector?
Key countries in the global hyperthyroidism therapeutics clinical trials sector are the US, the UK, the Netherlands, Denmark, Malaysia, Spain, Italy, Iran, and China.
-
Which are the key companies in the global hyperthyroidism therapeutics clinical trials sector?
Key companies in the global hyperthyroidism therapeutics clinical trials sector are Morningside Healthcare Ltd, Macleods Pharmaceuticals Ltd, Uni-Pharma SA, Roivant Sciences Ltd, Novartis AG, Health Sciences Acquisitions Corp 2, Beijing Yanjing Pharmaceutical Co Ltd, Beijing Borui Kangjian Pharmaceutical Technology Co Ltd, Beijing Baiao Pharmaceuticals Co Ltd, and AbbVie Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Hormonal Disorders reportsHyperthyroidism – Global Clinical Trials Review, H1, 2021
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
GlobalData's clinical trial report, “Hyperthyroidism – Global Clinical Trials Review, H1, 2021" provides an overview of Hyperthyroidism Clinical trials scenario. This report provides top line data relating to the clinical trials on Hyperthyroidism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global clinical trials landscape
– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
– The Report provides enrollment trends for the past five years
– Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to Buy
– Assists in formulating key business strategies with regards to investment
– Helps in identifying prominent locations for conducting clinical trials which saves time and cost
– Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
– Supports understanding of trials count and enrollment trends by country in global therapeutics market
– Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
– Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Macleods Pharmaceuticals Ltd
Uni-Pharma SA
Health Sciences Acquisitions Corp 2
Novartis AG
Roivant Sciences Ltd
AbbVie Inc
Beijing Baiao Pharmaceuticals Co Ltd
Beijing Yanjing Pharmaceutical Co Ltd
Beijing Zhongxin Pharmaceutical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.